Cargando…

Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS)

BACKGROUND: Long-term outcome data after hepatitis C virus (HCV) treatment are limited, particularly for comparisons between persons with and without HIV. METHODS: A5320 was a prospective cohort study that enrolled participants within 12 months of completing HCV DAA therapy, with or without sustaine...

Descripción completa

Detalles Bibliográficos
Autores principales: Wyles, David L, Kang, Minhee, Matining, Roy M, Murphy, Robert L, Peters, Marion G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061557/
https://www.ncbi.nlm.nih.gov/pubmed/37008564
http://dx.doi.org/10.1093/ofid/ofad115
_version_ 1785017316635836416
author Wyles, David L
Kang, Minhee
Matining, Roy M
Murphy, Robert L
Peters, Marion G
author_facet Wyles, David L
Kang, Minhee
Matining, Roy M
Murphy, Robert L
Peters, Marion G
author_sort Wyles, David L
collection PubMed
description BACKGROUND: Long-term outcome data after hepatitis C virus (HCV) treatment are limited, particularly for comparisons between persons with and without HIV. METHODS: A5320 was a prospective cohort study that enrolled participants within 12 months of completing HCV DAA therapy, with or without sustained virologic response (SVR). The primary end point was composite: time to death or development of a targeted diagnosis. Component outcomes (death and targeted diagnosis) and liver-related events were also analyzed. The effects of HIV serostatus, HIV RNA and CD4, and liver disease stage on the outcomes were assessed. Follow-up was designated for 5 years. RESULTS: Three hundred thirty-two participants enrolled: 184 with HIV/HCV (130 SVR) and 148 with HCV (125 SVR). The primary analysis was dominated by targeted diagnoses. Increased rates of targeted diagnoses were seen in HCV-HIV/SVR compared with HCV/SVR (P = .016), with an incidence rate of 6.7 and 3.4 per 100 person-years, respectively. Among persons without HIV, higher rates of targeted diagnoses were observed in non-SVRs (P = .007), 10.8 vs 3.4/100 person-years. No significant difference was seen by SVR status among those with HIV. There were 15 deaths; all liver-related deaths (n = 4) occurred in non-SVR groups. CONCLUSIONS: HCV cure following therapy reduces subsequent development of new clinical events, supporting the use of SVR as a predictor for clinical outcomes. Despite HIV control, a significant decrease in incident events or mortality was not demonstrated for people with HIV who achieved SVR, suggesting that coinfection attenuates the beneficial impact of SVR. Research is needed to better define mechanisms accounting for the long-term negative impact of controlled HIV infection.
format Online
Article
Text
id pubmed-10061557
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-100615572023-03-31 Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS) Wyles, David L Kang, Minhee Matining, Roy M Murphy, Robert L Peters, Marion G Open Forum Infect Dis Major Article BACKGROUND: Long-term outcome data after hepatitis C virus (HCV) treatment are limited, particularly for comparisons between persons with and without HIV. METHODS: A5320 was a prospective cohort study that enrolled participants within 12 months of completing HCV DAA therapy, with or without sustained virologic response (SVR). The primary end point was composite: time to death or development of a targeted diagnosis. Component outcomes (death and targeted diagnosis) and liver-related events were also analyzed. The effects of HIV serostatus, HIV RNA and CD4, and liver disease stage on the outcomes were assessed. Follow-up was designated for 5 years. RESULTS: Three hundred thirty-two participants enrolled: 184 with HIV/HCV (130 SVR) and 148 with HCV (125 SVR). The primary analysis was dominated by targeted diagnoses. Increased rates of targeted diagnoses were seen in HCV-HIV/SVR compared with HCV/SVR (P = .016), with an incidence rate of 6.7 and 3.4 per 100 person-years, respectively. Among persons without HIV, higher rates of targeted diagnoses were observed in non-SVRs (P = .007), 10.8 vs 3.4/100 person-years. No significant difference was seen by SVR status among those with HIV. There were 15 deaths; all liver-related deaths (n = 4) occurred in non-SVR groups. CONCLUSIONS: HCV cure following therapy reduces subsequent development of new clinical events, supporting the use of SVR as a predictor for clinical outcomes. Despite HIV control, a significant decrease in incident events or mortality was not demonstrated for people with HIV who achieved SVR, suggesting that coinfection attenuates the beneficial impact of SVR. Research is needed to better define mechanisms accounting for the long-term negative impact of controlled HIV infection. Oxford University Press 2023-03-06 /pmc/articles/PMC10061557/ /pubmed/37008564 http://dx.doi.org/10.1093/ofid/ofad115 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Wyles, David L
Kang, Minhee
Matining, Roy M
Murphy, Robert L
Peters, Marion G
Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS)
title Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS)
title_full Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS)
title_fullStr Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS)
title_full_unstemmed Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS)
title_short Adverse Impact of HIV-1 on Long-term Outcomes Following HCV DAA Treatment: Final Results of ACTG A5320, the Viral Hepatitis C Infection Long-term Cohort Study (VHICS)
title_sort adverse impact of hiv-1 on long-term outcomes following hcv daa treatment: final results of actg a5320, the viral hepatitis c infection long-term cohort study (vhics)
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061557/
https://www.ncbi.nlm.nih.gov/pubmed/37008564
http://dx.doi.org/10.1093/ofid/ofad115
work_keys_str_mv AT wylesdavidl adverseimpactofhiv1onlongtermoutcomesfollowinghcvdaatreatmentfinalresultsofactga5320theviralhepatitiscinfectionlongtermcohortstudyvhics
AT kangminhee adverseimpactofhiv1onlongtermoutcomesfollowinghcvdaatreatmentfinalresultsofactga5320theviralhepatitiscinfectionlongtermcohortstudyvhics
AT matiningroym adverseimpactofhiv1onlongtermoutcomesfollowinghcvdaatreatmentfinalresultsofactga5320theviralhepatitiscinfectionlongtermcohortstudyvhics
AT murphyrobertl adverseimpactofhiv1onlongtermoutcomesfollowinghcvdaatreatmentfinalresultsofactga5320theviralhepatitiscinfectionlongtermcohortstudyvhics
AT petersmariong adverseimpactofhiv1onlongtermoutcomesfollowinghcvdaatreatmentfinalresultsofactga5320theviralhepatitiscinfectionlongtermcohortstudyvhics